Mathias Svahn

This profile gathers the share dealings of Mathias Svahn in NextCell Pharma AB, where the filings describe the role as chief executive. Altogether 4 filings, all relating to 30 May 2025.

Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.

The latest filing, published on 3 June 2025, reports a transaction in NextCell Pharma AB. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 4 days. The regulation allows three business days to notify a trade (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.